英國啟動計畫以測試人工智慧在藥物研發中的應用
UK launches initiative to test AI in drug development
Updated at: June 10, 2026 at 03:00 AM
2026年6月9日，英國政府啟動了一項具有里程碑意義的計畫，旨在透過人工智慧的力量來徹底改變藥物開發。
On June 9, 2026, the UK government launched a landmark initiative to transform drug development through the power of artificial intelligence.
該計畫由英國藥品和醫療產品監管署(MHRA)主導，引入了一種獨特的「監管沙盒」。
Led by the Medicines and Healthcare products Regulatory Agency (MHRA), the project introduces a unique 'regulatory sandbox.'
這個受控的空間讓研究人員能夠與監管機構直接合作，確保人工智慧驅動的工具在進入患者體內前，是安全、準確且具備預測藥物副作用能力的。
This controlled space allows researchers to collaborate directly with regulators, ensuring that AI-driven tools are safe, accurate, and capable of predicting drug side effects before they reach patients.
這項計畫旨在解決傳統藥物開發中高達90%的失敗率。
The initiative addresses the daunting 90% failure rate in traditional drug development.
透過改進預測建模，英國目標在於大幅減少每年因藥物不良反應而導致的250,000次住院人數，進而為英國國家醫療服務體系(NHS)節省數十億英鎊。
By improving predictive modeling, the UK aims to drastically reduce the 250,000 annual hospitalizations caused by adverse drug reactions, saving the NHS billions.
此舉是英國更廣泛的「人工智慧科學」戰略的一部分，其中包括一個雄心勃勃的目標，即在2030年之前，在短短100天內開發出可進行臨床試驗的藥物。
This move is part of the UK’s broader 'AI for Science' strategy, which includes an ambitious goal to develop trial-ready drugs in just 100 days by 2030.
透過將先進的人工智慧整合到醫療流程中，英國正將自己定位為醫療科技的全球領導者，從理論研究轉向救命創新的實際戰略部署。
By integrating advanced AI into the medical pipeline, the UK is positioning itself as a global leader in health technology, shifting from theoretical research to the practical, strategic deployment of life-saving innovations.
